TRAIL-induced apoptosis of HL60 leukemia cells: Two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFα but not to idarubicin and cytarabine
- 1 January 2009
- journal article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 42 (1) , 77-84
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Targeting NF-κB in hematologic malignanciesCell Death & Differentiation, 2006
- NF-κB and IKK as therapeutic targets in cancerCell Death & Differentiation, 2006
- Mechanisms of resistance to TRAIL-induced apoptosis in cancerCancer Gene Therapy, 2004
- TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapyApoptosis, 2002
- Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κBNature Cell Biology, 2001
- Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell typesFEBS Letters, 2000
- Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- A novel receptor for Apo2L/TRAIL contains a truncated death domainCurrent Biology, 1997
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995